Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case- control study

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 222-229

  André, Marc ^a   Henry Amar, Michel ^a   Pico, José Luis ^a   Brice, Pauline ^a   Biaise, Didier ^a   Kuentz, Mathieu ^a   Coiffier, Bertrand ^a   Colombat, Philippe ^a   Cahn, Jean Yves ^a   Attal, Michel ^a   Fleury, Joël ^a   Milpied, Noël ^a   Nedellec, Gérard ^a   Biron, Pierre ^a   Tilly, Hervé ^a   Jouet, Jean Paul ^a   Gisselbrecht, Christian ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOGUAZONE; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032895067     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.222     Document Type: Article

References (26)

1. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1483, 1992
2. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992
3. Reece DE, Barnett MJ, Shepherd JD, et al: High-dose cyclophosphamide, carmustine, and etoposide with or without cisplatin and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451-456, 1995
4. Bonfante V, Santoro A, Viviani S, et al: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15:528-534, 1997
5. Gribben JG, Linch DC, Singer AK, et al: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340-344, 1989
6. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822, 1997
7. Cosset JM, Henry-Amar M, Meerwarldt JK, et al: The EORTC trials for limited stage Hodgkin's disease. Eur J Cancer 28A:1847-1850, 1992
8. Somers R, Carde P, Henry-Amar M, et al: A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 12:279-287, 1994
9. Henry-Amar M, Aeppli DM, Anderson J, et al: Workshop statistical report, in Somers R, Henry-Amar M, Meerwaldt JH, Carde P (eds): Treatment Strategy in Hodgkin's Disease. Colloque Inserm 196. Paris, Les Editions Inserm/John Libbey Eurotext, 1990, pp 169-418
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Cox DR: Regression models and life-tables. J R Stat Soc [B]33:187-220, 1972
12. Wartelle M, Kramar A, Jan P, et al: "Pigas": An interactive statistical database managment system, in Hammond R, McCarthy JL (eds): Proceedings of the Second International Workshop on Statistical Database Management, Los Altos, CA. Springfield, IL, National Technical Information Service, US Department of Commerce, 1983, pp 124
13. Stata Reference Manual: Release 3 (ed 5). Santa Monica, CA, Computing Resource Center, 1992
14. André M, Henry-Amar M, Biaise D, et al: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 92:1933-1940, 1998
15. Fermé C, Bastion Y, Lepage E, et al: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 6:543-549, 1995
16. Jagannath S, Dicke KA, Armitage JO, et al: High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104:163-168, 1986
17. Nademanee A, O'Donnel MR, Snyder DS, et al: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem-cell transplantation for patients with relapsed or refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 85:1381-1390, 1995
18. Santoro A, Viviani S, Valagussa P, et al: CCNU, etoposide, and prednimustine in refractory Hodgkin's disease. Semin Oncol 13:23-26, 1986
19. Roach M III, Kapp DS, Rosenberg SA, et al: Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol 5:550-555, 1987
20. Wirth A, Corry J, Laidlaw C, et al: Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiot Oncol Biol Phys 39:599-607, 1997
21. Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and autologous hematopoietic progenitor transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic index. Blood 89:801-813, 1997
22. Santoro A, Bonfante V, Bonnadonna G, et al: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139-143, 1982
23. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1474-1484, 1992
24. Gianni AM, Bregni M, Siena S, et al: High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease: A 6-year update. Ann Oncol 4:889-891, 1993
25. Bosly A, Guillaume T, Brice P, et al: Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol 20:962-968, 1992
26. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BLNI randomised trial. Lancet 341:1051-1054, 1993